Warsaw

• A Study of LY3437943 in Participants Who Have Obesity or Overweight (TRIUMPH-1) Ended
  2023-503657-35-00 5 2023-10-10 Obesity
• A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adult … Ended
  2022-502552-31-00 4 2023-10-03 Relapsing Forms of Multiple Sclerosis
• A Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis Ended
  2022-501621-20-00 5 2023-10-02 Prurigo Nodularis
• A Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis (The … Ended
  2024-512767-30-00 4 2023-09-28 Eosinophilic Esophagitis
• BP11 Versus EU-Approved Xolair® in Patients With Chronic Spontaneous Urticaria Ended
  2024-514764-72-00 5 2023-09-27 Chronic Urticaria
• A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis Ended
  2022-502888-38-00 4 2023-09-25 Atopic dermatitis
• A Ph3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Severe Hypertriglyceridemia: The ENTRUST study Ended
  2023-503576-25-00 5 2023-09-22 Severe Hypertriglyceridemia
• A Multi-national Phase IIIb Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 Years o … Ended
  2023-509833-38-00 5 2023-09-20 Birch Pollen-induced Allergic Rhinoconjunctivitis
• A double-blind, randomised, dose-finding trial to assess the efficacy, safety and pharmacokinetics of a single dose of albaconazole versus f … Ended
  2023-504727-32-00 4 2023-09-18 Acute vulvovaginal candidiasis
• A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab a … Ended
  2022-501895-25-00 5 2023-09-13 Polymyalgia Rheumatica
• A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis Ended
  2022-501476-25-00 5 2023-09-12 Atopic Dermatitis Eczema
• Study to Evaluate the Efficacy and Safety of Intranasal BPL-003 in Patients with Treatment Resistant Depression Ended
  2024-513457-70-00 4 2023-09-08 Treatment-Resistant Depression (TRD)
• An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis Ended
  2022-502994-40-00 4 2023-09-04 Rheumatoid Arthritis
• A randomized, placebo controlled, investigator and participant-blinded study, investigating safety, tolerability and efficacy of RHH646 in p … Ended
  2022-502821-16-00 4 2023-09-01 Knee Osteoarthritis
• A Study to Evaluate the Efficacy and Safety of Vixarelimab Compared with Placebo in Patients with Idiopathic Pulmonary Fibrosis and in Patie … Ended
  2022-502828-42-00 4 2023-09-01 Idiopathic Pulmonary Fibrosis
• A study to understand how well DC806 works and how safe it is in participants with plaque psoriasis Ended
  2022-502249-90-00 4 2023-08-31 Plaque Psoriasis
• To access the effect of SCD-044 in treatment of moderate to severe atopic dermatitis Ended
  2024-511615-16-00 4 2023-08-25 atopic dermatitis
• A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants with Heart Failure and … Ended
  2022-502382-25-00 4 2023-08-24 Heart Failure and Pulmonary Hypertension due to Left Heart Disease (WH
• Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer Ended
  2022-502196-31-00 10 2023-08-21 Advanced or Recurrent Endometrial Cancer
• A Phase III, open-label, randomized, controlled, multi-country study to evaluate the immune response, safety, and reactogenicity of respirat … Ended
  2022-501988-40-00 5 2023-08-17 RSV-associated (subtypes A and B) disease in adults aged 60 years of a
• A study to evaluate Intravitreal JNJ-81201887(AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary … Ended
  2022-500746-16-00 4 2023-08-11 Geographic Atrophy
• A multicentre, randomised, double-blind, placebo-controlled, 12-week parallel-group trial to evaluate the efficacy and safety of oral BP1.78 … Ended
  2022-502045-10-00 4 2023-08-11 Atopic dermatitis
• APTIVATE Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with … Ended
  2023-503244-14-00 7 2023-08-11 Relapsed or Refractory Acute Myeloid Leukemia (AML)
• A study evaluating the effects of GLPG3667 given as oral treatment for up to 24 weeks in adults with dermatomyositis Ended
  2022-501097-19-00 4 2023-08-09 dermatomyositis

Showing 1,441–1,464 of 1,708 trials